目錄:MedChemExpress LLC>>信號通路>> Esomeprazole sodium | 埃索美拉唑鈉 | MedChemExpress (MCE
CAS | 161796-78-7 | 純度 | 99.35% |
---|---|---|---|
分子量 | 367.4 | 分子式 | C??H??N?NaO?S |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 1 mg |
貨號 | HY-17023 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。
CAS No. : 161796-78-7
MCE 國際站:Esomeprazole sodium
產(chǎn)品活性:Esomeprazole sodium ((S)-Omeprazole sodium) 是一種有效的具有口服活性質(zhì)子泵 (proton pump) 抑制劑,可通過抑制胃壁細(xì)胞中的 H+, K+-ATPase 來降低酸分泌,并可用于胃食管反流疾病的研究。Esomeprazole 是一種外泌體抑制劑,通過抑制 V-H+-ATPases 來阻斷外泌體的釋放。
研究領(lǐng)域:Membrane Transporter/Ion Channel | Anti-infection
作用靶點(diǎn):Proton Pump | Bacterial
In Vitro: Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.
In Vivo: Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis.
相關(guān)產(chǎn)品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | Bioactive Compound Library Plus | Rapamycin | Doxorubicin hydrochloride | Bafilomycin A1 | Dexamethasone | Puromycin dihydrochloride | Dimethyl sulfoxide | Staurosporine | Actinomycin D | G-418 disulfate | Etoposide | 5-Azacytidine | Nigericin sodium salt | Brefeldin A | Estradiol | CCCP | Ionomycin | Resveratrol | Hygromycin B | Tunicamycin | Mitomycin C | Everolimus | Doxycycline hyclate | Tacrolimus | Methotrexate | Neomycin sulfate | Acetaminophen | Streptozotocin | Anisomycin | Cholesterol
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標(biāo)記物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)